You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth ...
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay o...
This issue of Cardiology Clinics, edited by Dr. Stephen Nicholls, focuses on Lipidology. Topics include, but are not limited to: Impact of lipoproteins on atherobiology; Lessons from genomic studies; Lipids and lipoproteins in risk prediction; Optimizing statins and ezetimibe in guideline focused management; Statin intolerance; Lipid lowering agents and diabetes risk; PCSK9 inhibitors; Bempedoic Acid; Triglyceride rich lipoproteins; Omega 3 Fatty Acids; Lipoprotein; CETP inhibitors; HDL infusions; and Targeting HDL functionality.
description not available right now.
In this Handbook of Experimental Pharmacology on “High Density Lipoproteins – from biological understanding to clinical exploitation” contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation. The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.
Non-thermal operations in food processing are an alternative to thermal operations and similarly aimed at retaining the quality and organoleptic properties of food products. This volume covers different non-thermal processing technologies such as high-pressure processing, ultrasound, ohmic heating, pulse electric field, pulse light, membrane processing, cryogenic freezing, nanofiltration, and cold plasma processing technologies. The book focuses both on fundamentals and on recent advances in non-thermal food processing technologies. It also provides information with the description and results of research into new emerging technologies for both the academy and industry. Key features: Present...
In this Handbook of Experimental Pharmacology on “High Density Lipoproteins – from biological understanding to clinical exploitation” contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation. The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.